Genetic signatures on prostate biopsy: clinical implications

Prostate cancer is the most common non-cutaneous malignancy in men with 161,000 new diagnoses in 2017 (1). It is a very heterogeneous disease with variable outcomes, depending on disease stage and grade. Due to serum prostate-specific antigen (PSA) screening of men at risk, most patients are diagnosed with indolent disease that does not impact quality of life or life expectancy and is therefore managed expectantly [active surveillance (AS)]. However, some patients will die of their cancer if left untreated